DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Read - 1 Eli Lilly - 1 Stacie Dusetzina - 1 Wegovy - 1 Eli Lilly's Mounjaro - 1 Evan Seigerman - 1 Eugene Yang - 1 Morningstar - 1
Top related locs:
New York Danish Washington
Top related orgs:
Novo Nordisk - 1 U.S - 1 Vanderbilt University - 1 Medicare - 1 Barclays - 1 University of Washington Medicine - 1 Companies - 1 Democratic - 1

Search resuls for: "University of Washington Medicine"


2 mentions found


☆ Obesity drug data could boost companies' case for US coverage, analysts say
  + stars: | 2023-08-10 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +5 min
Wegovy prescriptions were up 300% at their peak, according to data from Barclays, before supply issues began to hamper sales. A COMPELLING CASEAnalysts said the data made a compelling case for long-term health benefits of the drug. Analysts were divided on whether Medicare could potentially cover Wegovy as a cardiovascular treatment without a new law passing. Three doctors specializing in obesity treatment, including a cardiologist, were not sure whether such an indication would allow for Medicare coverage. Companies that provide healthcare insurance have begun pulling back on coverage of weight loss drugs because of the high cost of the medicines.
Persons: Read, Eli Lilly, Stacie Dusetzina, Wegovy, Eli Lilly's Mounjaro, Evan Seigerman, Eugene Yang, Morningstar, Damien Conover, Tom Carper, Eli Lilly's, Dusetzina, Patrick Wingrove, Elissa Welle, Ahmed Aboulenein, Caroline Humer Organizations: Novo Nordisk, U.S, Vanderbilt University, Medicare, Barclays, University of Washington Medicine, Companies, Democratic, Novo, Reuters, Democrat, Republican, Thomson Locations: New York, Danish, Washington
☆ Pfizer's Covid drug Paxlovid may reduce the risk of developing long Covid, study says
  + stars: | 2023-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
(Photo by Rachel Wisniewski/For the Washington Post)People who take Pfizer 's Covid antiviral treatment Paxlovid shortly after infection may reduce their risk of developing long Covid, regardless of their age, vaccination status or infection history, new research suggests. The study, published in the journal JAMA Internal Medicine on Thursday, found that people who took Paxlovid within five days of a positive Covid test saw a 26% lower risk of long Covid compared with those who didn't receive it. The new study comes as researchers work to fill the knowledge gap about long Covid, an often debilitating condition with limited data and no proven treatment available. Long Covid refers to new, returning or ongoing health issues more than four weeks after an initial Covid infection, according to the Centers for Disease Control and Prevention. She called the new study "very exciting and promising" because it's the first to show an association between Paxlovid and a decreased risk of long Covid.
0 next >>
Total: 2